Atherosclerosis Risk & Comprehensive Monitoring Panel
The Atherosclerosis Risk & Comprehensive Monitoring Panel delivers an in-depth cardiovascular assessment by measuring cholesterol, ApoA1, ApoB, Lipoprotein (a), Lp-PLA2, fibrinogen, insulin, HbA1c, thyroid function, kidney markers, inflammation, and blood counts. This advanced cardiometabolic panel evaluates lipid particles, vascular inflammation, metabolic balance, and clotting factors linked to long-term heart health.
- $1,420.86
- $398.45
- Save: 71.96%
The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: Microalbumin Random Urine with Creatinine
Creatinine, Random Urine
Microalbumin
Microalbumin/Creatinine
Apolipoprotein A1
Apolipoprotein B
Apolipoprotein B/A1 Ratio
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Absolute Band Neutrophils (Only Reported If Detected)
Absolute Basophils
Absolute Blasts (Only Reported If Detected)
Absolute Eosinophils
Absolute Lymphocytes
Absolute Metamyelocytes (Only Reported If Detected)
Absolute Monocytes
Absolute Myelocytes (Only Reported If Detected)
Absolute Neutrophils
Absolute Nucleated Rbc (Only Reported If Detected)
Absolute Promyelocytes (Only Reported If Detected)
Band Neutrophils (Only Reported If Detected)
Basophils
Blasts (Only Reported If Detected)
Eosinophils
Hematocrit
Hemoglobin
Lymphocytes
MCH
MCHC
MCV
Metamyelocytes (Only Reported If Detected)
Monocytes
MPV
Myelocytes (Only Reported If Detected)
Neutrophils
Nucleated Rbc (Only Reported If Detected)
Platelet Count
Promyelocytes (Only Reported If Detected)
RDW
Reactive Lymphocytes (Only Reported If Detected)
Red Blood Cell Count
White Blood Cell Count
Also known as: Chem 12, Chemistry Panel, Chemistry Screen, CMP, Complete Metabolic Panel, Comprehensive Metabolic Panel CMP, SMA 12, SMA 20
Albumin
Albumin/Globulin Ratio
Alkaline Phosphatase
Alt
AST
Bilirubin, Total
Bun/Creatinine Ratio
Calcium
Carbon Dioxide
Chloride
Creatinine
Egfr African American
Egfr Non-Afr. American
GFR-AFRICAN AMERICAN
GFR-NON AFRICAN AMERICAN
Globulin
Glucose
Potassium
Protein, Total
Sodium
Urea Nitrogen (Bun)
Also known as: Factor I, Fibrinogen, Fibrinogen Activity Clauss
Fibrinogen Activity,
Also known as: A1c, Glycated Hemoglobin, Glycohemoglobin, Glycosylated Hemoglobin, HA1c, HbA1c, Hemoglobin A1c, Hemoglobin A1c HgbA1C, Hgb A1c
HEMOGLOBIN A1C
Also known as: C-Reactive Protein, Cardio CRP, Cardio hs-CRP, CRP, High Sensitivity CRP, High-sensitivity C-reactive Protein, High-sensitivity CRP, Highly Sensitive CRP, hsCRP, Ultra-sensitive CRP
Hs Crp
Also known as: Insulin (fasting)
Insulin
Also known as: Cholesterol, HDL,Fasting Lipids,Cholesterol, LDL, Fasting Lipids, Lipid Panel (fasting), Lipid Profile (fasting), Lipids
Chol/HDLC Ratio
Cholesterol, Total
HDL Cholesterol
LDL-Cholesterol
Non HDL Cholesterol
Triglycerides
Also known as: Lipoprotein A, Lp (a), Lp(a)
Lipoprotein (A)
LP PLA2 ACTIVITY
Also known as: Free T3, FT3, T3 Free
T3, Free
Also known as: Free T4, FT4, T4 Free
T4, Free
Also known as: Thyroid Stimulating Hormone Test, Thyrotropin Test
TSH
The Atherosclerosis Risk & Comprehensive Monitoring Panel panel contains 14 tests with 75 biomarkers .
The Atherosclerosis Risk & Comprehensive Monitoring Panel is an extensive cardiovascular and cardiometabolic assessment designed to evaluate traditional risk markers, advanced lipoprotein parameters, inflammatory activity, coagulation factors, thyroid function, kidney health, and metabolic balance. This panel integrates foundational heart health biomarkers with advanced vascular and endocrine markers to provide a detailed picture of factors associated with atherosclerosis and long-term cardiovascular risk.
Atherosclerosis is a complex, progressive condition involving lipid accumulation, inflammation, endothelial dysfunction, metabolic imbalance, and coagulation pathway activation. Rather than focusing on cholesterol alone, this panel examines multiple biological systems that contribute to arterial plaque formation and cardiovascular disease progression. It includes a Lipid Panel, Apolipoprotein A1 and B, Lipoprotein (a), Lp-PLA2 Activity, fibrinogen activity, and high-sensitivity C-reactive protein (hs-CRP) to evaluate lipid transport, vascular inflammation, and clotting potential.
Metabolic and endocrine contributors are also assessed through Hemoglobin A1c, fasting insulin, a Comprehensive Metabolic Panel (CMP), thyroid markers (TSH, Free T4, Free T3), and urine albumin-to-creatinine ratio testing. These biomarkers provide insight into glucose regulation, insulin resistance, kidney function, thyroid balance, and systemic metabolic health—key factors influencing cardiovascular outcomes.
The inclusion of a Complete Blood Count (CBC) with Differential and Platelets further supports evaluation of hematologic health, inflammatory response, and platelet levels involved in clot formation. Together, these measurements offer a multidimensional cardiovascular risk profile that supports preventive health planning and long-term monitoring.
This panel is designed for individuals seeking a comprehensive, data-driven assessment of cardiometabolic and vascular health, aligning with evidence-based strategies for advanced cardiovascular screening and ongoing risk management.
When and Why Someone Would Order This Panel
Advanced Cardiovascular Risk Evaluation
This panel may be considered by individuals who want a thorough cardiovascular assessment that goes beyond standard cholesterol testing. While LDL cholesterol remains an important risk marker, additional measurements such as Apolipoprotein B, Lipoprotein (a), Lp-PLA2 activity, and fibrinogen provide deeper insight into lipoprotein particle burden, inherited cardiovascular risk, vascular inflammation, and thrombotic tendency.
Individuals with a family history of premature cardiovascular disease or prior abnormal lipid results may seek more detailed stratification of their atherosclerotic risk.
Cardiometabolic and Insulin Resistance Monitoring
Insulin resistance, impaired glucose control, and metabolic syndrome significantly contribute to atherosclerosis. Hemoglobin A1c and fasting insulin together help evaluate long-term glycemic exposure and insulin sensitivity. These markers are especially useful for individuals monitoring weight management, nutrition programs, or metabolic health changes under medical supervision.
Thyroid and Metabolic Influence on Lipids
Thyroid dysfunction can significantly affect cholesterol levels, triglycerides, and overall metabolic rate. Including TSH, Free T4, and Free T3 allows for assessment of thyroid balance, which can influence lipid metabolism and cardiovascular risk patterns.
Kidney and Vascular Health Screening
The Albumin Random Urine with Creatinine test evaluates microalbuminuria, an early indicator of endothelial and kidney damage. Even small increases in urine albumin can reflect vascular injury and elevated cardiovascular risk.
Ongoing Comprehensive Monitoring
This panel may also be ordered for longitudinal tracking of cardiovascular biomarkers. Individuals implementing lifestyle changes, nutritional interventions, or physician-directed therapies may use this assessment to monitor trends in lipid particles, inflammatory markers, insulin regulation, and coagulation factors over time.
What Does the Panel Measure?
Lipid and Lipoprotein Markers
-
Lipid Panel: Total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides.
-
Apolipoprotein A1 (ApoA1): Major protein component of HDL particles, associated with reverse cholesterol transport.
-
Apolipoprotein B (ApoB): Reflects the number of atherogenic lipoprotein particles, including LDL and VLDL.
-
Lipoprotein (a) [Lp(a)]: A genetically influenced lipoprotein associated with increased cardiovascular risk.
Vascular Inflammation and Plaque Activity
-
hs-CRP: Measures low-grade systemic inflammation linked to cardiovascular risk.
-
Lp-PLA2 Activity: An enzyme associated with vascular inflammation and plaque instability.
-
Fibrinogen Activity: A coagulation factor that contributes to clot formation and may reflect thrombotic risk.
Glucose and Insulin Regulation
-
Hemoglobin A1c: Reflects average blood glucose over approximately three months.
-
Fasting Insulin: Assesses insulin production and sensitivity, providing insight into insulin resistance.
Organ Function and Metabolic Balance
-
Comprehensive Metabolic Panel (CMP): Evaluates kidney function, liver enzymes, electrolytes, glucose, and protein levels.
-
Albumin Random Urine with Creatinine: Detects early kidney damage and endothelial dysfunction.
Thyroid Function
-
TSH, Free T4, Free T3: Evaluate thyroid regulation, hormone production, and metabolic rate.
Hematologic Assessment
-
Complete Blood Count (CBC) with Differential and Platelets: Measures red and white blood cells, hemoglobin, hematocrit, and platelet levels, offering insight into oxygen transport, immune response, and clotting potential.
How Patients and Healthcare Providers Use the Results
Comprehensive Cardiovascular Risk Stratification
Healthcare providers use this panel to evaluate multiple contributors to atherosclerosis simultaneously. Elevated ApoB, high Lp(a), increased Lp-PLA2 activity, elevated hs-CRP, and abnormal fibrinogen levels may collectively suggest increased vascular inflammation, plaque instability, or thrombotic risk.
Identification and Monitoring of Conditions
This panel may help identify or monitor:
-
Dyslipidemia
-
Metabolic syndrome
-
Insulin resistance
-
Prediabetes and diabetes
-
Subclinical vascular inflammation
-
Thyroid dysfunction
-
Early kidney impairment
-
Prothrombotic states
Because cardiovascular disease often develops over decades, early identification of risk patterns supports proactive health planning.
Personalized Intervention Planning
Results may guide individualized strategies such as dietary adjustments, structured exercise programs, weight management approaches, thyroid optimization under medical supervision, or physician-directed therapies targeting lipid or inflammatory pathways. Advanced markers allow for more precise decision-making beyond traditional cholesterol measurements alone.
Longitudinal Monitoring
Tracking changes in ApoB, Lp(a), insulin, HbA1c, thyroid markers, Lp-PLA2, and fibrinogen over time provides insight into how lifestyle or medical interventions influence cardiometabolic and vascular health. Trend analysis enables data-informed adjustments and supports long-term prevention strategies.
The Atherosclerosis Risk & Comprehensive Monitoring Panel offers a broad and integrated evaluation of cardiovascular, metabolic, inflammatory, endocrine, and coagulation-related biomarkers. By examining multiple biological pathways involved in plaque formation and vascular disease, this panel reflects the complexity of atherosclerosis and cardiometabolic health.
Rather than focusing solely on cholesterol levels, this comprehensive assessment incorporates advanced lipoprotein testing, inflammatory markers, insulin regulation, thyroid function, kidney health, and clotting factors. This multidimensional approach supports informed discussions between patients and healthcare providers and encourages proactive, personalized health strategies.
Regular monitoring of these biomarkers can provide meaningful insight into long-term cardiovascular wellness. Understanding how lipid particles, inflammation, metabolism, endocrine function, and vascular integrity interact allows for a more complete perspective on heart and vascular health.